Related Experiment Videos
Neuroimaging in Parkinson's disease.
1Medical Research Council Clinical Sciences Center and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London W12 0NN, United Kingdom. david.brooks@csc.mrc.ac.uk
Summary
Positron emission tomography and single photon emission computed tomography show promise as biomarkers for diagnosing and tracking Parkinson's disease (PD) progression. These functional imaging techniques can also evaluate treatments and reveal underlying pharmacological changes in PD.
Area of Science:
- Neurology
- Medical Imaging
- Pharmacology
Background:
- Parkinson's disease (PD) is a progressive neurodegenerative disorder.
- Accurate diagnosis and monitoring of PD progression are crucial for effective management.
- Current diagnostic and monitoring methods have limitations.
Purpose of the Study:
- To review the role of positron emission tomography (PET) and single photon emission computed tomography (SPECT) in Parkinson's disease.
- To evaluate the utility of these functional imaging techniques as biomarkers.
- To assess their potential in evaluating neuroprotective agents and understanding PD pathophysiology.
Main Methods:
- Review of existing literature on PET and SPECT applications in Parkinson's disease.
- Analysis of studies focusing on diagnostic and prognostic value.
- Examination of research on assessing therapeutic interventions and pharmacological changes.
Main Results:
- PET and SPECT can serve as valuable biological markers for PD diagnosis.
- These imaging modalities aid in monitoring disease progression.
- Functional imaging can assess the efficacy of neuroprotective agents and reveal pharmacological changes.
Conclusions:
- PET and SPECT are promising tools for Parkinson's disease management.
- Functional imaging can offer objective measures of treatment efficacy.
- These techniques will likely become essential adjuncts to clinical assessment in future PD research and care.